ES2052502T3 - Interferones hibridos, su empleo como medicamentos y como productos intermedios para la preparacion de anticuerpos y su empleo, asi como procedimiento para su preparacion. - Google Patents

Interferones hibridos, su empleo como medicamentos y como productos intermedios para la preparacion de anticuerpos y su empleo, asi como procedimiento para su preparacion.

Info

Publication number
ES2052502T3
ES2052502T3 ES87103030T ES87103030T ES2052502T3 ES 2052502 T3 ES2052502 T3 ES 2052502T3 ES 87103030 T ES87103030 T ES 87103030T ES 87103030 T ES87103030 T ES 87103030T ES 2052502 T3 ES2052502 T3 ES 2052502T3
Authority
ES
Spain
Prior art keywords
preparation
new
well
omega
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87103030T
Other languages
English (en)
Inventor
Rudolf Hauptmann
Peter Swetly
Peter Meindl
Guenther Adolf
Edgar Falkner
Gerhard Bodo
Ingrid Maurer-Fogy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2052502T3 publication Critical patent/ES2052502T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Soft Magnetic Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCION SON LOS NUEVOS INTERFERONES HIBRIDOS QUE TIENEN UNA PARTE DE ALFA-INTERFERON Y UNA PARTE DE GAMMA-INTERFERON CUYOS N TERMINALES SON DERIVADOS METILICOS O N-FORMIL-METILO Y EN EL CASO DE LA SECUENCIS PEPTIDICA DEL INTERFERON HIBRIDO CONTIENE UNA POSICION DE GLUCOSILACION. SON TAMBIEN OBJETO EL DERIVADO DE N-GLUCOSILICO; SU UTILIZACION COMO MEDICAMENTO Y COMO PRODUCTO INTERMEDIO PARA LA INMUNIZACION DE ANIMALES DE ENSAYO, ASI COMO LOS PROCEDIMIENTOS DE PREPARACION, NUEVOS ANTICUERPOS MONOCLONALES, SU UTILIZACION Y SU EMPLEO PARA LA PURIFICACION DE LAS ALFA Y OMEGA INTERFERONAS DE LAS CUALES SE SEPARAN CELULAS HIBRIDAS Y SU PREPARACION, UN NUEVO PROCEDIMIENTO DE PURIFICACION DE ALFA Y OMEGA INTERFERONES CON AYUDA DE UNA COLUMNA DE AFINIDAD POR LOS ANTICUERPOS, QUE CONTIENEN LOS NUEVOS ANTICUERPOS MONOCLONALES, Y EL METODO DE SU FABRICACION, NUEVOS PLASMIDOS HIBRIDOS PARA LA MEJORA DE LA EXPRESION DE LOS OMEGA-INTERFERONES Y NUEVOS PLASMIDOS INTERMEDIOS PARALA OBTENCION DE LOS NUEVOS PLASMIDOS ASI COMO EL METODO DE SU PREPARACION.
ES87103030T 1986-03-10 1987-03-04 Interferones hibridos, su empleo como medicamentos y como productos intermedios para la preparacion de anticuerpos y su empleo, asi como procedimiento para su preparacion. Expired - Lifetime ES2052502T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863607835 DE3607835A1 (de) 1986-03-10 1986-03-10 Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
ES2052502T3 true ES2052502T3 (es) 1994-07-16

Family

ID=6295926

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87103030T Expired - Lifetime ES2052502T3 (es) 1986-03-10 1987-03-04 Interferones hibridos, su empleo como medicamentos y como productos intermedios para la preparacion de anticuerpos y su empleo, asi como procedimiento para su preparacion.

Country Status (21)

Country Link
US (1) US4917887A (es)
EP (1) EP0236920B1 (es)
JP (1) JPS62282595A (es)
KR (1) KR950008191B1 (es)
AT (1) ATE81671T1 (es)
AU (1) AU600702B2 (es)
DD (2) DD266118A5 (es)
DE (2) DE3607835A1 (es)
DK (1) DK120387A (es)
ES (1) ES2052502T3 (es)
FI (2) FI925631A0 (es)
GR (1) GR3006844T3 (es)
HU (1) HU206896B (es)
IE (2) IE60573B1 (es)
IL (1) IL81832A0 (es)
NO (1) NO870967L (es)
NZ (1) NZ219549A (es)
PH (1) PH27060A (es)
PT (1) PT84427B (es)
SU (1) SU1604164A3 (es)
ZA (1) ZA871679B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
AT389318B (de) * 1987-10-22 1989-11-27 Boehringer Ingelheim Int Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
US5000940A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Devices, compositions and the like having or containing an inorganic pyrophosphate
US5047231A (en) * 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
US5000943A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Canine biscuits containing an inorganic pyrophosphate
US5000973A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Nutritionally-balanced canine biscuits containing an inorganic pyrophosphate
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
AU770018B2 (en) * 1998-03-13 2004-02-12 Brown University Research Foundation Human N-type calcium channel isoform and uses thereof
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US20020197235A1 (en) 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
WO2003016472A2 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9902770B2 (en) * 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
JPH064673B2 (ja) * 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
AU1155083A (en) * 1982-01-19 1983-07-28 Cetus Corporation Multiclass hybrid interferons
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
DE3584198D1 (de) * 1984-08-01 1991-10-31 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
DE3428370A1 (de) * 1984-08-01 1986-02-13 Boehringer Ingelheim International GmbH, 6507 Ingelheim Interferon, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen
EP0174143B1 (en) * 1984-08-27 1989-11-08 Genentech, Inc. Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators

Also Published As

Publication number Publication date
HUT44074A (en) 1988-01-28
IE870591L (en) 1987-09-10
ATE81671T1 (de) 1992-11-15
US4917887A (en) 1990-04-17
FI925631L (fi) 1992-12-11
PH27060A (en) 1993-02-01
DE3782259D1 (de) 1992-11-26
DK120387A (da) 1987-09-11
IE940131L (en) 1987-09-10
EP0236920B1 (de) 1992-10-21
EP0236920A2 (de) 1987-09-16
JPS62282595A (ja) 1987-12-08
GR3006844T3 (es) 1993-06-30
AU6978687A (en) 1987-09-17
SU1604164A3 (ru) 1990-10-30
AU600702B2 (en) 1990-08-23
HU206896B (en) 1993-01-28
IL81832A0 (en) 1987-10-20
NO870967D0 (no) 1987-03-09
NZ219549A (en) 1990-07-26
NO870967L (no) 1987-09-11
EP0236920A3 (en) 1988-03-02
PT84427A (de) 1987-04-01
IE60573B1 (en) 1994-07-27
FI925631A7 (fi) 1992-12-11
DD266118A5 (de) 1989-03-22
KR950008191B1 (ko) 1995-07-26
FI925631A0 (fi) 1992-12-11
DD276493A5 (de) 1990-02-28
FI871012A0 (fi) 1987-03-09
DE3607835A1 (de) 1987-09-24
KR870009020A (ko) 1987-10-22
ZA871679B (en) 1988-11-30
DK120387D0 (da) 1987-03-09
FI871012A7 (fi) 1987-09-11
PT84427B (pt) 1989-10-04

Similar Documents

Publication Publication Date Title
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
FR2319338A1 (fr) Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
DK120387A (da) Hybridinterferoner, deres anvendelse som laegemiddel og mellemprodukter til fremstilling af antistoffer og disses anvendelse samt fremgangsmaade til deres fremstilling
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
ES2036737T3 (es) Procedimiento para la obtencion de mezclas farmaceuticas.
NL191793C (nl) Werkwijze voor de bereiding van een polypeptide, en van een farmaceutisch of veterinair preparaat.
PT73161A (fr) Procede pour la preparation de derives de n-(vynblastinoyl-23) aux amino-acids et peptides et son application terapeutique
FI803849A7 (fi) Uudet asyylipeptidit, niistä valmistetut farmaseuttiset valmisteet, menetelmä niiden valmistamiseksi ja niiden käyttö.
NL191234C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat voor de behandeling van aandoeningen van de ademhalingswegen.
BE800779A (fr) Derives d'acide bis(4-hydroxyphenyl)alcanoiques et medicaments qui en contiennent
FI870808L (fi) 9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
SE7608120L (sv) Avgivningssystem for anestetika
ATA1034373A (de) Verfahren zur herstellung von fur die gewinnung diagnostischer und therapeutischer allergenpraparate verwendbaren extrakten
BE794226A (fr) Derives de la quinoleine, leur preparation et les medicaments qui en contiennent
NO138083C (no) Anlegg for kontinuerlig vulkanisering av langstrakte vulkaniserbare produkter
BE821920R (fr) Derives de la benzophenone et medicaments qui en contiennent
ATE118331T1 (de) Apparat für die verabreichung von medikamenten für die veterinärmedizin.
AT345447B (de) Verfahren zur herstellung von stabilen, injizierbaren, vitamin b12 und entzuendungshemmer enthaltenden arzneimitteln
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
SE9003902D0 (sv) Solid dosage forms of a drug
NL7609140A (nl) Werkwijze voor de bereiding van een dierlijk eiwitconcentraat.
ATA356675A (de) Apparat zur direkten bluttransfusion
AT317418B (de) Verfahren zur Herstellung von intravenös beim Menschen anwendbarem Humanalbumin aus menschlichen Placenten
AR224765A1 (es) Metodo controlado para el fraccionamiento rapido de proteinas del plasma sanguineo y metodo para la concentracion de proteinas de dicho plasma
AT288596B (de) Verfahren zur Herstellung pharmazeutischer Präparate

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 236920

Country of ref document: ES